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Abstract 
Purpose: To investigate whether some herbal compounds, namely, arctiin, NSC333050, cnicin, and 
arctigenin, can be used as anti-tubercular agents using in vivo and in silico techniques. 
Methods: A set of structurally diverse herbal compounds were screened for anti-tubercular activity 
against the Mycobacterium tuberculosis (Mtb) H37v strain by determining their microbial inhibitory 
concentration (MIC) and cytotoxicity. The compounds were also screened using in silico techniques, 
such as molecular docking and absorption, distribution, metabolism, and excretion (ADME) prediction.  
Results: The in vivo methods, such as determination of MIC and cytotoxicity assay, revealed that some 
of the herbal compounds showed superior anti-tubercular activity. In silico approaches involving 
molecular docking simulations for the mycobacterial enzymes Mtb DNA gyrase, Mtb betalactamase, Mtb 
diaminopelargonic acid synthase, and Mtb cytidine 5'-triphosphate synthase (CTP) confirmed that the 
inhibitory activities of the herbal compounds occurred at the active sites of these enzyme. In silico 
ADME prediction also confirmed the pharmacokinetic safety of these herbal compounds. 
Conclusion: Arctiin, NSC333050, cnicin, and arctigenin, are suitable candidates for clinical evaluation 
for the treatment of respiratory infections caused by Mtb. 
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Tuberculosis (TB) is an infection that mainly 
affects the lungs, impairing respiratory function 
and causing other complications [1]. The 
symptoms include cough, fever, haemoptysiss, 
and weight loss [2]. TB remains prevalent in 
many regions [3]. Mycobacterium tuberculosis 
(Mtb) is the pathogenic bacterium that causes 
pulmonary tubercular infection. The number of 
deaths due to active TB infection has increased 
at an alarming rate [4,5], and it has been 
estimated that approximately 2 billion people are 
infected with latent or active Mtb worldwide [6].  
In addition, new multi-drug-resistant MDR-Mtb 
strains and extensively drug-resistant (XDR-Mtb) 
strains have emerged and spread to more than 
58 countries [7,8], which has complicated 
treatment  [9].  The protocols for treating TB also 
take a long time and are expensive. Hence, new 
anti-TB drugs and better therapeutic strategies 
against TB are urgently needed [10,11]. 
 
In recent years, focus [12]. At present, some 
compounds are in clinical trial, while others are in 
the pre-clinical investigation stage [13]. In 
addition, many researchers have reported on 
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compounds that possess strong anti-tubercular 
activity, but these were not entered into clinical 
trials due to health-related complications [14]. In 
view of these concerns over health risks, this 
investigation focused on the in vivo screening of 
certain compounds present in herbal plants for 
anti-tubercular activity, which could prevent 
respiratory infection. It also involved in silico 
approaches such as molecular docking 
simulations, which revealed that the compounds 
inhibit certain mycobacterial enzymes. In silico 
absorption, distribution, metabolism, and 
excretion (ADME) prediction of compounds that 
dock at the active sites of the enzymes was also 
carried out, and it revealed that some such 
compounds are promising for treating TB and 
could potentially help in the fight against 
respiratory infections. These compounds have a 
very low risk of health-related hazards, as most 






A 35 herbal compounds present in herbal 
medicinal plants were purchased from ABI Chem 
(Munich, Germany) and Sigma-Aldrich (St. Louis, 
MI, USA). All of the commercial reagents and 
media were purchased from Sigma Aldrich and 
Hi Media (Paris, France), and the cell lines were 
supplied by the hospital authorizing the study. 
The names of the chemicals and their two-
dimensional structures, PubChem IDs, and 
herbal plant sources are presented in Table ST1 
in the supplementary material. 
 
Determination of microbial inhibitory 
concentration (MIC) 
 
The anti-mycobacterial activity was assessed by 
determining the MIC values against the Mtb 
H37Rv strain using the microbroth dilution 
method [15,16]. Initially, all of the 35 herbal 
compounds, along with isoniazid (control), were 
dissolved in dimethyl sulfoxide (DMSO) at 10 
mg/mL and stored at 80 °C. The compound 
stocks were further diluted with Middlebrook 7H9 
medium and adjusted to a final volume of 100 
μL. The stocks were then dispensed in a 96-well 
round-bottomed microtitre plate using the serial 
dilution method. In addition, a standard log-
phase bacterial suspension (MtbH37Rv strain) 
grown in Middlebrook 7H9 medium was 
prepared, to which 0.05 % Tween 80 was added 
at 35 °C to achieve absorbance of 0.005,  
corresponding to 100 colony-forming units/mL 
[17]. The inocula were then added to drug plates 
to give a total volume of 200 μL, with final drug 
concentrations beginning at 200 μg/mL. The 
plates were then sealed and incubated for 12 
days at 37 °C, and the minimum concentration of 
the drug that inhibited bacterial growth at a rate 
of more than 90 % was determined. The MIC 
was determined as the minimum compound 
concentration at which the well was clear, 
indicating that no bacterial growth had occurred. 
 
Determination of cytoxicity 
 
The cytotoxicity assay was performed by 
culturing Vero epithelial cells (ATCC No. CCL-
81) and Jurkat cells (T-lymphocyte line, ATCC 
No. CRL-2676) in Dulbecco’s modified Eagle’s 
medium supplemented with 5 or 10 % foetal calf 
serum, respectively [18]. The cell lines were 
grown at 37 °C in a 96-well plate in an 
atmosphere of 5 % CO2. Cytotoxicity (CD50), 
which represents the concentration that results in 
mortality of 50 % of the cells, was estimated by 
incubating the uninfected cells at concentrations 
in the range of 0 – 100 μg/mL for 72 h along with 
the herbal compounds, followed by the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) cell proliferation assay. The MTT 
assay was performed as described by 
Mossmann (1983). First, the assay was 
optimised for the cell lines, incubated for 4 h with 
0.8 mg/ml MTT, dissolved in serum-free medium, 
and washed with 1–2 ml of phosphate-buffered 
saline (PBS) (1 ml). This was followed by the 
addition of 1 ml of DMSO and shaking of the 
mixture for 10 min, to achieve complete 
dissolution. Approximately 200-μl samples of the 
resulting aliquots were then transferred to 96-well 
plates and used for measurement of absorbance 
at 560 nm using a microplate spectrophotometer 
system [19]. The compounds were then 
dissolved at a concentration of 40 mg/mL with 




To check the molecular interactions of the herbal 
compounds with mycobacterial enzymes, 
molecular docking studies were carried out 
against proteins of the Mtb H37v strain using 
MVD 5.0 [20]. Specifically, the molecular docking 
simulations were performed against Mtbs DNA 
gyrase (PDB ID: 3IG0); Mtb betalactamase 
(MtbBlac; PDB ID: 4QHC); Mtb 
diaminopelargonic acid synthase, a Bio A 
enzyme (PDB ID: 4XEW); and Mtb cytidine 5′-
triphosphate synthase synthase (CTP), a PyrG 
enzyme (PDB ID: 4ZDI). Initially, the potential 
ligand binding of these enzymes was predicted 
using a cavity detection program implemented in 
MVD 5.0. Subsequently, the protein was 
stabilised in accordance with the protein 
preparation protocol of MVD 5.0. The potential 
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ligand binding sites of these four enzymes were 
predicted using MVD 5.0. Here, the method for 
detecting a potential ligand binding site involves 
a grid-based cavity prediction algorithm, in which 
a discrete grid with a resolution of 0.8 Å is 
created and placed in a 1.4-Å-radius sphere. 
Whether the sphere overlaps with the protein 
atoms’ van der Waals radii was then 
investigated. Then, each accessible grid point 
was further checked to determine whether it was 
part of a cavity. The final step was to determine 
the connected regions. The identified cavities 
were then ranked according to their volume [21].  
 
The 2D structures of the 36 compounds along 
with isoniazid (for validation) were also retrieved 
from the PubChem database and converted to 
3D format; then, and their geometries were 
optimised using HyperChem7.0 [22]. The 
optimised 3D structures of the herbal compounds 
were loaded in MVD, and their bond flexibility 
was set. The root-mean-square deviation 
threshold for multiple cluster poses was set at 
2.00 Å. The docking algorithm was set at a 
maximum of 1500 iterations with a simplex 
evolution size of 50; a minimum of 50 docking 
simulation runs were carried out, and the best 
pose was chosen. Finally, ADME prediction was 
carried out for the compounds that docked at the 




Statistical analysis was carried out using 
Microsoft Excel 2010 to determine correlations 
with in vivo results. In addition, the energy 
parameters generated in the docking simulation 
were analysed using Molegro Data Modeller 2.0 
[26]. Docking scores were ranked based on 
parameters such as rerank score, interaction 




In vivo and in silico studies of 36 compounds 
were carried out for anti-tubercular screening 
against the Mtb H37v strain. These revealed that 
arctiin, NSC333050, cnicin, capsaicin, 
campesterol, sophoricoside, arctigenin, shogaol, 
and rhamnetin exhibited strong anti-microbial 
activities. In this study, the MIC was defined as 
the minimum concentration of the herbal 
compound required to induce complete inhibition 
of mycobacterial growth. The MIC values of 
these compounds were found to be lower than 
that of isoniazid (control), as shown in Table 1.  
 
From screening this set of structurally diverse 
herbal compounds, the PubChem Bioassay 
database showed that most of these herbal 
compounds have not been subjected to anti-
tubercular screening. Hence, the MIC values 
presented here constitute novel data. The MIC 
value was lowest for arctiin, at 0.64 µg/mL, while 
that of campesterol was 0.86 µg/ml, which is very 
close to the MIC value of isoniazid (0.89 µg/ml). 
The MIC values of gomisin A and gingerol were 




Table 1: MIC values of the herbal compounds against Mtb H37Rv strain 
 
S/N Compound MIC (µg/ml) S/N Compound MIC (µg/ml) 
1 Alliin 27 19 Eugenol 150 
2 Aloe emodin >25 20 Gingerol <200 
3 Apigenin >25 21 Gomisin A <200 
4 Arctigenin 0.63 22 Isoniazid 0.89 
5 Arctiin 0.64 23 Isorhamnetin >50 
6 Bisabolol 100 24 Kaempferol 100 
7 Campesterol 0.86 25 Myricetin >75 
8 Capsaicin  0.82 26 Nordihydroguaiaretic acid 125 
9 Chamazulene 100 27 NSC333050  0.71 
10 Cnicin 0.76 28 Rhamnetin 7.3 
11 Cycloartenol 34 29 Shogaol 10 
12 Cycloastragenol 100 30 Sophoricoside 1.2 
13 Daphnoretin >25 31 Stigmasterol >100 
14 Ellagic Acid  30 32 Tetrandrine 25 
15 Emodin >25 33 Thymol 50 
16 Ephedrine Hydrochloride  >25 34 Vanillin 22 
17 Eugenin 50 35 Zingerone 100 
18 Eugenitin 12.5    
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Table 2: Cytotoxicity of compounds with MIC lower 
than that of isoniazid 
 
Compound CD50 (μg/mL) 
Vero Jurkat 
Arctiin 1 >100 100 
NSC333050  >200 100 
Cnicin >100 100 
Capsaicin  >400 >300 
Campesterol >200 150 
Sophoricoside >500 400 
Arctigenin >100 >200 
Shogaol >400 >100 
Rhamnetin >300 >100 
Isoniazid >400 >400 
CD50 - represents the concentration that results in 
mortality of 50 % of the cells of Vero – Lineages of 
cells isolated from kidney epithelial cells extracted 
from an African green monkey; Jurkat – Immortalized 
cell line of human T lymphocyte cells 
 
To understand the adverse effects of the herbal 
compounds, the cell cytotoxicity of those 
compounds with an MIC lower than that of 
isoniazid (0.89 µg/ml) was studied in Vero and 
Jurkat cell cultures. Table 2 shows the cell 
cytotoxicity levels of the herbal compounds, 
which may result in a variety of cell fates, such 
as necrosis and cell lysis. 
 
Table 3 shows the molecular docking scores of 
the bioactive compounds present in the herbal 
plants against four different enzymes, namely 
Mtb DNA gyrase (PDB ID: 3IG0);  MtbBlac (PDB 
ID:4QHC); Mtb diaminopelargonic acid synthase, 
BioA (PDB ID: 4XEW); and MtbCTP synthase, a 
PyrG (PDB ID: 4ZDI). The scores and results for 
the molecular docking simulations based on the 
rerank score, interaction energy, and hydrogen 
bonding energy are shown in Table 3. The 
overall docking scores revealed that arctiin, 
cnicin, NSC333050, and arctigenin inhibited 
these mycobacterial enzymes. Images depicting 
the molecular interactions are presented in 
Figure 1, Figure 2, Figure 3 and Figure 4 for the 
top docking hits for these enzymes. 
Physiochemical properties such as hydrogen 
bond donor, hydrogen bond acceptor, and 
molecular weight, which might contribute to the 
biological properties of these herbal compounds, 
are shown in Table 4. Lastly, the in silico ADME 
prediction results for the top docking hit 




Screening of 34 herbal compounds revealed that 
arctiin, NSC333050, cnicin, capsaicin, 
campesterol, sophoricoside, arctigenin, shogaol, 
and rhamnetin possess strong anti-tubercular 
activities. The MIC values of these compounds 
were found to be better than that of isoniazid 
(Table 1), indicating that they possess 
synergistically enhanced anti-tubercular 
activities. Determination of the MIC against Mtb 
of various herbal compounds has also been 
reported by Lall et al [23]. They reported the 
effectiveness of herbal compounds with lower 
MIC values, which is consistent with the present 
report. Furthermore, McGaw et al reported the 
effectiveness of herbal compounds at inhibiting 
various mycobacterial species compared with  
 






PDB ID: 3IG0    
Arctiin -89.36 -151.91 -2.99 
C333050  -88.75 -145.54 -2.74 
Cnicin -86.65 -140.64 -3.54 
Sophoricoside -84.61 -140.96 -12.21 
Capsaicin  -83.94 -149.81 -3.31 
Gingerol -83.64 -111.82 -5.41 
Arctigenin -80.21 -119.08 -2.40 
Isoniazid -78.10 -119.26 -2.12 
Cycloartenol -75.80 -122.25 -0.73 
PDB ID: 4XEW    
Arctiin -99.45 -156.04 -8.92 
NSC333050  -95.57 -110.39 -4.98 
Stigmasterol -92.44 -122.15 -2.50 
Cnicin -90.52 -114.19 -10.46 
Arctigenin -92.04 -127.15 -9.75 
Campesterol -91.40 -129.44 -0.82 
Isoniazid -91.24 -143.25 -2.67 
Rhamnetin -83.75 -123.06 -10.91 
Shogaol -79.21 -104.11 -5.09 
PDB ID: 4XEW    
Arctiin -107.85 -163.23 -13.58 
Cnicin -103.61 -118.98 -13.42 
Arctigenin -98.98 -130.43 -4.11 
NSC333050  -95.00 -108.88 -1.85 
Capsaicin  -92.41 -133.23 -0.77 
Sophoricoside -90.82 -128.54 -17.26 
Cycloastrage
nol -90.05 -118.87 -9.19 
Campesterol -89.77 -127.50 -4.46 
Stigmasterol -85.69 -123.85 0.00 
PDB ID: 4ZDI    
Arctiin -107.39 -156.90 -5.40 
Arctigenin -103.41 -141.52 -11.21 
NSC333050  -103.13 -130.31 -9.27 
Sophoricoside -92.73 -151.46 -9.33 
Stigmasterol -90.93 -121.72 0.00 
Rhamnetin -89.88 -138.08 -8.93 
Cnicin -88.12 -116.53 -6.05 
Isoniazid -87.38 -119.88 -2.00 
Cycloartenol -87.06 -129.78 0.00 
Rerank score - The rerank score is a linear 
combination of E-inter (steric, Van der Waals, 
hydrogen bonding, electrostatic) between the ligand 
and the protein, and E-intra; Interaction - The total 
interaction energy between the pose and the protein 
(kJ mol-1); Hbond - Hydrogen bonding energy (kJ mol-
1) 
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Figure 1: Molecular interaction of (a) Arcitin with Thr542, Gln565, Tyr610 residues (b) NSC333050 with Arg634 
and (c) Cnicin with Gln538, Ser541, Gln565, Arg634 residues of 3IGO 
 
 
Figure 2: Molecular interaction of (a) Arctiin with Arg115, Ile117, Asp255, Asn186, Thr253, Thr251, Lys87 (b) 
NSC333050: Ile117, Lys87 (c) Stigmasterol with Glu292, Thr232 residues of 4QHC 
 
 
Figure 3: Molecular interaction of (a) Arctiin with Tyr25, Ser27, Arg30, Glu31, Val36, Trp398, Arg400 (b) Cnicin 
with Trp64, Gly124, Ser125, Tyr157, Lys283, Leu290, Leu292 (c) Arctigenin with Arg400 residues of 4XEW 
 
 
Figure 4: Molecular interaction of (a) Arctiin with Ala19, Thr156 (b) Arctigenin with Ala19, Ser21, Leu22, Gly23, 
Lys24, Gly25, Lys46, Thr156 (c) NSC333050 with Leu22, Gly23, Lys24, Lys46, Gly155, Thr156 residues of 4ZDI 
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    Table 4: Physiochemical properties of arctiin, NSC333050, cnicin, arctigenin and isoniazid 
 
Compound MW HBA HBD XLog P3 Rot B TPSA (Å2) 
Arctiin 534.55 11 4 1.8 10 153 
NSC333050  348.39 6 0 2.3 3 77.7 
Cnicin 378.41 3 7 0.2 6 113 
Arctigenin 372.41 6 1 3.6 7 74.2 
Isoniazid 137.13 3 3 -0.7 1 68.0 
MW – Molecular weight; HBA – Hydrogen bond acceptor; HBD – Hydrogen bond donor; XLog P3 – Computed 
octanol-water partition coefficient; Rot B – Number of rotatable bonds; TPSA - Topological polar surface area  
 
Table 5: In silico ADME prediction for arctiin, NSC333050, cnicin, arctigenin and isoniazid 
 






Arctiin 97 0.009 1.02 30 
NSC333050  100 0.053 1.46 30 
Cnicin 100 0.034 1.11 30-70 
Arctigenin 100 0.051 1.52 30 
Isoniazid 90 0.005 0.9 <70 
 
synthetic drugs available on the market [24]. 
Among the nine most active herbal compounds, 
none of the compounds was properly 
investigated for its anti-tubercular activity in 
previous studies. Hence, the MIC values 
presented here constitute novel data on these 
compounds. 
 
The cell cytotoxicity tests of these compounds in 
this study showed that arctiin, cnicin, and 
arctigenin have lower cell toxicity levels than the 
rest of the tested compound, with CD50 values of 
less than 100 μg/mL (Table 2) in both Vero and 
Jurkat cell cultures. Cytotoxicity assays were 
performed for the compounds with MIC values 
lower than that of isoniazid. The CD50 values of 
the tested compounds in Vero cells were lower 
than the toxicity level of the drug isoniazid, which 
has been approved for public use (Table 2). The 
CD50 values of the tested herbal compounds 
demonstrate that they have a good safety profile 
compared with isoniazid. 
 
The scoring function for molecular docking 
studies carried out using MVD 5.0 (Table 3) is 
based on the modified piecewise linear potential 
with new hydrogen bonding and electrostatic 
terms [27]. In these studies, only the top three 
docking hits were considered based on the 
rerank scores, which is a linear combination of E-
inter (including van der Waals, steric, hydrogen 
bonding, and electrostatic forces) between the 
ligand and the protein, and E-intra (including van 
der Waals, hydrogen bonding, torsion, sp2-sp2, 
and electrostatic forces of the ligand) weighted 
by pre-defined coefficients [27]. 
 
In the first simulation carried out against Mtb 
DNA gyrase (PDB ID: 3IG0), arctiin, 
NSC333050, and cnicin inhibited the active site 
of the enzyme, with rerank scores of −89.36, 
−88.75, and −86.65 kJ mol-1, respectively (Table 
3: 3IG0). In the second simulation performed 
against MtbBlac (PDB ID: 4QHC), arctiin, 
NSC333050, and stigmasterol inhibited this 
enzyme with rerank scores of −99.45, −95.57, 
and −92.44 kJ mol-1, respectively (Table 3: 
4QHC). In the third simulation, arctiin, cnicin, and 
arctigenin inhibited diaminopelargonic acid 
synthase, a BioA enzyme (PDB ID: 4XEW), with 
rerank scores of −107.85, −103.61, and −98.98 
kJ mol-1, respectively (Table 3: 4XEW). Lastly, 
arctiin, arctigenin, and NSC333050 inhibited CTP 
synthase, a PyrG enzyme (PDB ID: 4ZDI), with 
rerank scores of −107.39, −103.41, and −103.13 
kJ mol-1, respectively (Table 3: 4ZDI). Images of 
the molecular interactions are shown in Figures 
1–4, where the interacting amino acids are 
highlighted. In the present investigation, the most 
promising herbal compounds with regard to anti-
tubercular activity based on MIC values, cell 
cytotoxicity assay, and molecular docking score 
are arctiin, NSC333050, cnicin, and arctigenin. 
These inhibitors displayed considerable in vitro 
and in silico anti-tubercular activities.  
 
Among the investigated Mtb enzymes, arcitiin 
interacts with the Thr542, Gln565, and Tyr610 
residues of Mtb DNA gyrase; the Arg115, Ile117, 
Asp255, Asn186, Thr253, Thr251, and Lys87 
residues of MtbBlac; the Tyr25, Ser27, Arg30, 
Glu31, Val36, Trp398, and Arg400 residues of 
Mtb diaminopelargonic acid synthase; and the 
Ala19 and Thr156 residues of Mtb CTP. This 
reflects the fact that arcitiin has the most potent 
anti-tubercular activity. The increased anti-
tubercular activity of these compounds compared 
with that of isoniazid may be due to the 
increased numbers of hydrogen bond donors and 
acceptors of these compounds (Table 4). 
Statistical analysis using Pearson’s correlation 
revealed a weak correlation between the MIC 
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values and the CD50 for Vero cells (r = 0.345), 
whereas no significant correlation was 
established for Jurkat cells (r = −0.358). 
However, an intermediate correlation was 
established between the CD50 values of Vero and 
Jurkat values (r = 0.671).  
 
In addition, in silico ADME absorption, 
distribution, metabolism, and excretion 
predictions revealed the favourable 
pharmacokinetic behaviour of these herbal 
compounds regarding their disposition in the 
human body (Table 5). The results show that 
these herbal compounds may be promising for 
the development of drugs for the treatment of 




Arctiin, NSC333050, cnicin, and arctigenin are 
promising anti-tubercular agents, based on the 
results of in vivo and in silico investigations. As 
these compounds are constituents of herbal 
medicinal plants, they have a low risk of side 
effects. Thus, it seems that these compounds are 
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